To examine trends for use of transhiatal esophagectomy (THE) and to relate outcome variables to changes in use, controlling for preoperative risk.
Objective
To examine trends for use of transhiatal esophagectomy (THE) and to relate outcome variables to changes in use, controlling for preoperative risk.
Background
High operative morbidity and mortality rates are reported with conventional transthoracic esophagectomy (TTE). Transhiatal esophagectomy has been proposed as an alternative but is controversial.
Methods
In this retrospective study divided into early and late time periods, outcome variables were subjected to univariate and multivariate analyses.
Results
Use of THE increased significantly in the late period (p < 0.0001). Patients who had THE had significantly higher American Society of Anesthesiologists (ASA) risk scores (p < 0.001). By the late period, 92% of patients with ASA III/IV scores were resected by THE. Postoperative morbidity decreased significantly and operative mortality decreased from 15% to 0% (p < 0.01) between the early and late time periods. By multivariate analysis, ASA 2 I l l and TTE were associated with adverse surgical outcome. Pathologic stage determined disease-free survival, which was 37% at 3 years for all survivors.
Conclusions
Increased use of THE results in better operative outcome and does not adversely affect diseasefree survival.
In 1980 Earlam and colleagues' reviewed 83,783 cases of esophageal cancer reported in the surgical literature in the preceding 20 years and reported a 29% operative mortality rate, concluding that esophageal cancer resec-tion has the "highest operative mortality ofany routinely performed surgical procedure today." The most widely used method for esophageal cancer resection then was transthoracic esophagectomy (TTE) according to the method of Lewis,2 and the application ofa combined abdominal and thoracic procedure in patients who were often debilitated, as well as the hazards of an intrathoracic esophagogastric anastomosis, contributed in large part to the reported high operative mortality rate.
In 1978, Orringer and Sloan3 reintroduced transhiatal We divided the study into an early phase (1/81 to 3/ 87) and a late phase (4/87 to 6/93) to permit evaluation of trends in the use of the two procedures as well as the morbidity and mortality rates and disease-free survival during the study. Statistical analysis was done using BMDP statistical package (BMDP Statistical Software, Los Angeles, CA) on a personal computer. Univariate statistics using means and standard deviations, and proportions (percentages) were used to describe the demographics, risk status, cancer stage, and the median disease-free survival for the entire sample. The analysis then proceeded to the bivariate and multivariate techniques to achieve the study objectives.
To achieve the first objective, patients' demographic, operative morbidity, and operative mortality variables were compared for the two time periods using Pearson chi-square test or Fisher's exact test for independent proportions. The Mantel-Haeszel chi-square test was used whenever stratified analysis was appropriate. Two-group means comparison using the t-test was done to compare continuous variables, such as age and hospital stay, for the two time periods. Similar analytic tools were used to compare the two operative procedures' outcomes at the bivariate level to achieve the second study objective.
Development of substantial postoperative cardiopulmonary complications (defined as myocardial infarction, congestive heart failure, arrhythmia, pneumonia, or pulmonary insufficiency requiring ventilator support for more than 48 hours) was analyzed as an outcome variable using multiple logistic regression models, including the time period and operative procedures together with other potentially confounding variables as independent variables. Effect modification (statistical interaction) by time or any significant variable in the model was carefully reviewed and its significance level reported. The magnitude of the effects was reported in terms of odds ratios, their 95% confidence interval, and their significance level. Cox multivariate proportional hazards regression modeling was used to compare the 3-year disease-free survival for the two operative procedures and time periods. Modeling strategies similar to those used in the logistic regression analysis were used in the survival analysis. However the magnitude of effects were reported in terms of relative risks rather than odds ratios. Table 2 lists general descriptive statistics for the overall patient population and by time period. No significant differences were noted between the two time periods in mean patient age, sex, histologic type, stage distribution, tumor location, or use of preoperative chemotherapy or radiotherapy. During the late period, the percentage of patients with ASA status of III or IV increased from 3 1% to 49%, which was ofborderline significance (p < 0. 1).
RESULTS

Patient Population
Time Trends in Use of THE and TTE
The use of transhiatal esophagectomy increased significantly over time from 27% of patients in the early period to 80% of patients in the late period (p < 0.0001; Table 3 ). The increased use of THE occurred only for cancers of the lower esophagus and esophagogastric junction, for which the use of THE increased from 17% in the early period to 83% in the late period (p < 0.0001; Table 3 ). No change was noted in use of THE for cancer of the mid and upper thoracic esophagus between the two time periods. The ASA risk status was significantly worse for THE patients than for TTE patients during both the early and the late periods (p < 0.001; Table 3 ). Furthermore, 92% of patients with ASA risk status greater than or equal to III had THE in the late period compared with 50% of patients in the early period (p < 0.025; Table 3 ). In addition, 95% of patients 65 years or older had THE in the late period compared with 38% in the early period (p < 0.001; Table 3 ). The TTE. Although such a finding has not been reported specifically for esophageal cancer resection, it is consistent with several previous studies12-'4 correlating operative morbidity and mortality with ASA risk status for major abdominal and thoracic surgical procedures.
Between the early and late periods of the study, use of THE for all patients increased significantly, particularly for high-risk patients who did poorly after TTE during the early period ofthe study.
The effect of increased THE use on operative mortality rate was dramatic, with a reduction to 0% in the late period. The mortality with TTE also decreased in the second time period (although not significantly, probably because of the small number of patients involved). This probably represents more careful selection of patients in light of the significant trend toward avoiding TTE in high-risk patients in the late period. The effect ofthe shift in use of the operative procedure on hospital length of stay and postoperative cardiopulmonary morbidity was also significant, and multivariate analysis revealed that the type of operative procedure and the preoperative ASA risk status were the major independent variables predictive of postoperative cardiopulmonary morbidity.
Multivariate disease-free survival analysis revealed that stage is the dominant prognostic variable for disease-free survival and that neither the type of operative procedure nor the period of study affected disease-free survival significantly. Cancers ofthe mid-thoracic esophagus fared significantly more poorly than did patients with tumors of the upper and lower esophagus, regardless of the type of surgical procedure used.
Several nonrandomized retrospective studies compared the efficacy oftranshiatal and transthoracic esophageal cancer resection and have not noted improved short-term results with transhiatal resection as we did in this study.78 In those studies, coanalysis ofthe preoperative risk status to rule out adverse selection of patients for THE was not done. In our own study, such analysis indicates that preoperative risk status predicts the frequency of postoperative morbidity and also predicts the risk for operative death for transthoracic resection. In view of this, the significantly lower postoperative morbidity rate and nonexistent mortality after THE are even more impressive, given the significantly worse ASA risk scores for patients undergoing THE. Although we noted no correlation between ASA risk status and the risk for operative death for transhiatal patients, the number of ASA IV patients having transhiatal resection is small and we cannot conclude a lack of correlation between risk status and death after THE for these patients at high risk. If such patients were included in significant numbers in other studies, this might lead to a significantly different short-term outcome after THE than was noted in our study.
We found significant shifts in patterns of use of THE and TTE in our hospital, especially for high-risk patients (ASA 2111), and we noted significantly decreased postoperative complication rates, postoperative length of stay, and operative mortality rates associated with this shift in use. Together these trends represent a dramatic change in the surgical approach to and early postoperative results after esophageal cancer resection in our institution. Regrettably the increased use of THE was not associated with better long-term disease-free survival, nor did evidence show that adoption of THE compromised long-term disease-free survival. The relatively lower use of THE for mid-esophageal cancers in both periods of the study and the reduced survival of this subgroup of patients highlights the limitations of THE and any alternative surgical approach for cancers of this region. DR. JOHN S. BOLTON (Closing Discussion): In response to Dr. Sawyers's questions, we have not noted as impressive a result with neoadjuvant therapy as he has, nor have we studied it as systemically as he has. We use neoadjuvant therapy primarily for the patient with a marginally resectable lesion in order to downstage them and facilitate their resection. In the absence of any clear-cut evidence otherwise that neoadjuvant improves survival, we've elected to take a surgical approach initially to restore swallowing in patients as quickly and as efficiently as possible. In essence then, I think our patients who are treated with neoadjuvant therapy tend to be the bulkier tumors. And while we've not had any indication that preoperative therapy is beneficial either in a univariate or multivariate analysis, clearly, I think we're adversely selecting them. In terms of our preoperative staging, we rely primarily on the preoperative CT scan. We're not using endoscopic ultrasound. And again I think our philosophy is primarily that our aim is to as quickly as possible resect the tumor to restore swallowing. The level of invasion in the esophageal wall in most cases does not determine resectability and nor does the presence of periesophageal nodes determine whether or not the surgeon can resect the tumor itself in the esophageal wall. So that we've not used that. It might be helpful if you were systematically studying neoadjuvant therapy, but since we're not doing that we've not used the preoperative endoscopic ultrasound. In response to Dr. Kron's question about the indications for transthoracic resection, clearly, we feel that in a good-risk patient, transthoracic resection is accompanied by relatively low operative mortality. And so in the good-risk patient, probably either technique is acceptable, although we feel strongly that the complication rate, the length of stay, and the recovery will all be better after the transhiatal resection. So that as Dr. Sawyers mentioned, the problem is the patient with the mid-esophageal tumor. That's the one for which, I think, in many ways we don't have a good resection by either technique. The fact is that a bulky mid-esophageal cancer in most cases will be adherent to the carina or the trachea, and even by the transthoracic route, the radial or circumferential margins around the tumor are often inadequate. I agree that those are the patients in whom the preoperative neoadjuvant therapy can be of benefit. For those patients with the midesophageal cancers, we will typically attempt a transhiatal resection and convert if it's clear that we can't make headway by that technique. And I think that in our hands that remains probably the biggest and the main indication for transthoracic resection at this time.
